Comparative performance of two automated machine learning platforms for COVID-19 detection by MALDI-TOF-MS
The 2019 novel coronavirus infectious disease (COVID-19) pandemic has resulted in an unsustainable need for diagnostic tests. Currently, molecular tests are the accepted standard for the detection of SARS-CoV-2. Mass spectrometry (MS) enhanced by machine learning (ML) has recently been postulated to...
Saved in:
Published in | PloS one Vol. 17; no. 7; p. e0263954 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
San Francisco
Public Library of Science
29.07.2022
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The 2019 novel coronavirus infectious disease (COVID-19) pandemic has resulted in an unsustainable need for diagnostic tests. Currently, molecular tests are the accepted standard for the detection of SARS-CoV-2. Mass spectrometry (MS) enhanced by machine learning (ML) has recently been postulated to serve as a rapid, high-throughput, and low-cost alternative to molecular methods. Automated ML is a novel approach that could move mass spectrometry techniques beyond the confines of traditional laboratory settings. However, it remains unknown how different automated ML platforms perform for COVID-19 MS analysis. To this end, the goal of our study is to compare algorithms produced by two commercial automated ML platforms (Platforms A and B). Our study consisted of MS data derived from 361 subjects with molecular confirmation of COVID-19 status including SARS-CoV-2 variants. The top optimized ML model with respect to positive percent agreement (PPA) within Platforms A and B exhibited an accuracy of 94.9%, PPA of 100%, negative percent agreement (NPA) of 93%, and an accuracy of 91.8%, PPA of 100%, and NPA of 89%, respectively. These results illustrate the MS method’s robustness against SARS-CoV-2 variants and highlight similarities and differences in automated ML platforms in producing optimal predictive algorithms for a given dataset. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: N.T. is a consultant for Roche Diagnostics and Roche Molecular Systems. He is also a co-inventor / co-owner of MILO-ML, LLC. H.R. is also a co-inventor / co-owner of MILO-ML, LLC. J.P. is a co-founder and employee of SpectraPass, LLC. L.M. is a consultant for Roche Diagnostics and Roche Molecular Systems. S.A. is a co-inventor / co-owner of MILO-ML, LLC. T.H., K.K., B.P., and M.S. have no competing interests. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0263954 |